

**Funding options that PHARMAC had before it during 2009/10 that were not funded (implemented) during that year**

These options comprise any proposal for funding potentially under consideration by PHARMAC at any stage between 1 July 2009 and 30 June 2010 that were not funded during that time.

The list includes any funding proposals that were under active consideration; assessed but not under active consideration; recommended decline by PTAC; undergoing assessment (therefore not yet prioritised); waiting for clinical information (e.g. PTAC review) before they could be further progressed; and approved in 2009/10 but not funded until 2010/11.

The list includes all funding proposals received by PHARMAC since 2008 (which will also be included in the web application tracker). All efforts have been made to include all historic funding proposals received before then, but some of these may inadvertently not have been included.

The patient population is an estimate of the number of people to be treated with the medicine (often provided by the applicant), and is expressed as a broad range. The range does not take into account any possible targeting mechanisms that may apply should a funding decision be made.

| Pharmaceutical  | Funding Requested For   | Patient Population |
|---|---|--------------------|
| Abacavir/lamivudine/zidovudine                                  | HIV infection   | 1,000-10,000       |
| Adapalene   | Acne - first line   | 10,000-50,000      |
| PKU Supplementation (Add-ins)                                   | Phenylketonuria (PKU)   | 100-1000           |
| Adrenaline Auto-injector  | Anaphylaxis   | 1,000-10,000       |
| Agalsidase alfa   | Fabry disease (a-galactosidase A deficiency) - Enzyme replacement therapy (ERT) | <100               |
| Alemtuzumab   | Chronic lymphocytic leukemia - third line                                       | <100               |
| Alglucosidase alfa (Myozyme)                                    | Pompe's disease   | <100               |
| Aliskiren   | Hypertension  | 50,000+            |
| Aminioacid Formula without phenylalanine (PKU Anamix Junior LQ) | Phenylketonuria (PKU)   | <100               |
| Atomoxetine   | Attention Deficit Hyperactivity Disorder (ADHD) - increased access              | 10,000-50,000      |
| Azacitidine   | Myelodysplastic syndromes   | 100-1000           |
| Bevacizumab   | Metastatic colorectal cancer - first line                                       | 100-1000           |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical                             | Funding Requested For  | Patient Population |
|--|--|--------------------|
| Bevacizumab                                | Metastatic colorectal cancer confined to the liver   | 100-1000           |
| Bimatoprost 0.03% and timolol maleate 0.5% | Open-angle glaucoma (OAG) or ocular hypertension (OHT)   | 1,000-10,000       |
| Bortezomib                                 | Induction therapy  | 100-1000           |
| Bortezomib                                 | Multiple Myeloma, Relapsed refractory - second line  | 100-1000           |
| Bortezomib                                 | Multiple Myeloma in patients ineligible for stem cell transplant - first line                    | 100-1000           |
| Brimonidine Tartrate 0.15%                 | Glaucoma   | 10,000-50,000      |
| Budesonide                                 | Crohn's disease (steroid dependency and longer SA period); and gut Graft vs. Host disease.       | 100-1000           |
| Budesonide (Entocort CIR)                  | Crohn's disease - patients with psychiatric problems and patients with relapse during pregnancy  | 100-1000           |
| Budesonide (Entocort CIR)                  | Microscopic colitis  | 100-1000           |
| Budesonide with eformoterol                | Asthma   | 50,000+            |
| Buprenorphine patches                      | Persistent moderate to severe pain   | 100-1000           |
| Buprenorphine/naloxone                     | Detoxification and maintenance treatment of opioid dependence                                    | 1,000-10,000       |
| Calcipotriol and betamethasone             | Psoriasis  | 10,000-50,000      |
| Candesartan                                | Heart Failure (widening access to allow combination with an ACEi)                                | 1,000-10,000       |
| Capecitabine                               | Adjuvant high risk stage II colorectal cancer  | 100-1000           |
| Capecitabine                               | Neoadjuvant rectal cancer  | 100-1000           |
| Cinacalcet hydrochloride                   | Secondary hyperparathyroidism  | <100               |
| Ciprofloxacin and hydrocortisone ear drops | Chronic suppurative otitis media   | 10,000-50,000      |
| Clopidogrel                                | Transient Ischemic Attack (TIA) - high risk patients   | 1,000-10,000       |
| Clopidogrel                                | Stroke + Transient Ischemic Attack (TIA) - alternative to aspirin and dipyridamole combo therapy | 1,000-10,000       |
| Clopidogrel                                | Acute Coronary Syndrome (ACS) - widening access to 12 months (from 3 months)                     | 1,000-10,000       |
| Clopidogrel                                | Drug-Eluting Stents (DES) - widening access to 12 months (from 6 months)                         | 1,000-10,000       |
| Clopidogrel                                | Cardio vascular disease - Widening of access to include patients intolerant to aspirin           | 1,000-10,000       |
| Cox 2 inhibitors                           | Haemophilia with arthropathy   | 100-1000           |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical                    | Funding Requested For   | Patient Population |
|-----------------------------------|---|--------------------|
| Dabigatran                        | Stroke, systemic embolism, atrial fibrillation  | 10,000-50,000      |
| Dabigatran                        | Prevention of venous thrombosis following orthopaedic surgery   | 1,000-10,000       |
| Darunavir                         | HIV infection (patients who have failed at least 3 antiretroviral regimens)                                       | 100-1000           |
| Darunavir                         | HIV infection   | 1,000-10,000       |
| Dasatinib                         | Bridge to allogenic transplant in patients with a defined donor   | <100               |
| Deferasirox                       | Congenital anaemia with resulting chronic iron overload in patients (all ages) contraindicated to desferrioxamine | <100               |
| Deferasirox                       | Congenital anaemia with resulting chronic iron overload in patients (all ages) intolerant to desferrioxamine      | <100               |
| Deferiprone                       | Congenital anaemia with resulting chronic iron overload in patients (all ages) contraindicated to desferrioxamine | <100               |
| Deferiprone                       | Congenital anaemia with resulting chronic iron overload in patients (all ages) intolerant to desferrioxamine      | <100               |
| Desogestrel                       | Contraception   | 50,000+            |
| Dipyridamole 200mg                | Stroke prophylaxis  | 1,000-10,000       |
| Dipyridamole 200mg + aspirin      | Stroke prophylaxis  | 1,000-10,000       |
| Docetaxel                         | Early breast cancer   | 100-1000           |
| Donepezil                         | Alzheimer's disease (Dementia)  | 10,000-50,000      |
| Dornase Alfa                      | Cystic fibrosis - widening of access FEV1 $\leq$ 75% predicted  | 100-1000           |
| Duloxetine                        | Treatment-resistant major depression  | 1,000-10,000       |
| Elemental Formula (Alfare)        | Cow's milk protein allergy, food intolerance and hypersensitivity   | 1,000-10,000       |
| Elemental Formula (Neocate Nutra) | Food allergies  | 1,000-10,000       |
| Erlotinib                         | Non-Small Cell Lung Cancer (NSCLC)  | <100               |
| Erythropoietin                    | Anaemia in cancer patients  | 100-1000           |
| Escitalopram                      | Depression  | 10,000-50,000      |
| Etravirine                        | HIV infection (patients who have failed at least 3 antiretroviral regimens)                                       | <100               |
| Everolimus                        | Prevention of rejection of renal/cardiac transplants  | <100               |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical                            | Funding Requested For   | Patient Population |
|---|---|--------------------|
| Exenatide                                 | Type 2 diabetes   | 100-1000           |
| Ezetimibe                                 | Hyperlipidemia (add-on to atorvastatin)   | 10,000-50,000      |
| Female condoms                            | STI prevention and contraception  | 50,000+            |
| Fentanyl low dose patches                 | Pain  | 100-1000           |
| Folic Acid                                | Supplementation in pregnancy (0.4mg to replace 0.8mg tablet)                          | 10,000-50,000      |
| Food Thickeners                           | Dysphagia   | 1,000-10,000       |
| Fulvestrant                               | Locally advanced or metastatic breast cancer - third line                             | <100               |
| Galantamine                               | Alzheimer's disease (Dementia)  | 10,000-50,000      |
| Gefitinib                                 | Non Small Cell Lung Cancer (NSCLC)  | <100               |
| Gemcitabine                               | Pancreatic cancer   | 100-1000           |
| Gemcitabine                               | Locally advanced or metastatic cholangiocarcinoma                                     | <100               |
| Gemfibrozil                               | Hypercholesterolemia patients intolerant to statins                                   | 100-1000           |
| Gluten free foods                         | Amendment to SA biopsy requirement  | 10,000-50,000      |
| Gluten free Gluten                        | Coeliac disease   | 1,000-10,000       |
| Gluten Free Multi-seed bread mix (Bakels) | Coeliac disease   | 1,000-10,000       |
| Golimumab                                 | Rheumatoid arthritis - second-line TNF inhibitor                                      | 100-1000           |
| Golimumab                                 | Psoriatic Arthritis - second line TNF Inhibitor                                       | 100-1000           |
| Golimumab                                 | Ankylosing spondylitis - second line TNF Inhibitor                                    | 100-1000           |
| High dose fluticasone/salmeterol          | Asthma and COPD   | 1,000-10,000       |
| Homocystinuria (HCU) Cooler               | Homocystinuria  | <100               |
| Hydrolysed rice protein formula (Risolac) | Cows milk protein intolerance   | 1,000-10,000       |
| Idursulfase                               | Hunter syndrome (Mucopolysaccharidosis II, MPS II) - Enzyme replacement therapy (ERT) | <100               |
| Imatinib                                  | Gastrointestinal Stromal Tumor (GIST), C-kit Negative                                 | <100               |
| Imatinib                                  | Chronic myelogenous leukemia (CML) - allow doses higher than 400mg (600mg max)        | <100               |
| Imiquimod                                 | Actinic keratosis   | 50,000+            |
| Insulin aspart 30/70                      | Type 1 diabetes   | 1,000-10,000       |
| Insulin detemir                           | Type 1 diabetes - second line LA insulin  | 100-1000           |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical                                  | Funding Requested For   | Patient Population |
|---|---|--------------------|
| Interferon beta-1-a (rch)                       | Multiple Sclerosis (MS) - relapsing-remitting   | 1,000-10,000       |
| Iodine  | Supplementation for pregnancy and breast feeding  | 50,000+            |
| Isopropyl alcohol 95% and anhydrous glycerin 5% | Swimmers ear  | 10,000-50,000      |
| Ketamine  | Palliative care patients with intractable pain not adequately controlled with opioids.                          | 100-1000           |
| Ketogenic diet formula (Ketocal)                | Chronic intractable epilepsy  | <100               |
| Ketotifen fumarate                              | Treatment of ocular allergy   | <100               |
| Lacosamide                                      | Epilepsy  | 100-1000           |
| Lanreotide                                      | Acromegaly and Neuroendocrine tumours   | 100-1000           |
| Lapatinib                                       | Advanced/metastatic HER-2 positive breast cancer  | <100               |
| Laronidase                                      | Mucopolysaccharidosis I (MPS I) to treat the non-neurological manifestations - Enzyme replacement therapy (ERT) | <100               |
| Latanoprost with timolol                        | Glaucoma  | 1,000-10,000       |
| Latex oral dams                                 | Prevention of STI transmission  | 50,000+            |
| Lenalidomide                                    | Multiple Myeloma  | 100-1000           |
| levofloxacin                                    | Helicobacter pylori- 2nd line use   | 10,000-50,000      |
| Levonorgestrel Implants                         | Long acting reversible contraception  | 10,000-50,000      |
| levonorgestrel Intraurine system                | Long acting reversible contraception  | 10,000-50,000      |
| Losartan  | Gout  | 10,000-50,000      |
| Metoclopramide oral liquid                      | Nausea and vomiting   | 1,000-10,000       |
| Metronidazole                                   | Bacterial vaginosis   | 10,000-50,000      |
| Mianserin                                       | Depression, treatment-resistant   | 1,000-10,000       |
| Milk substitute formula (S-26 Gold)             | Premature infants   | 1,000-10,000       |
| Modafinil                                       | Narcolepsy - last-line treatment  | 1,000-10,000       |
| Modafinil                                       | Narcolepsy - open listing   | 1,000-10,000       |
| Modulen IBD                                     | Crohn's Disease   | 1,000-10,000       |
| Montelukast                                     | Asthma - aspirin induced (AIA)  | 1,000-10,000       |
| Montelukast                                     | Asthma - exercise induced (EIA)   | 1,000-10,000       |
| Montelukast                                     | Asthma - patients intolerant to inhaled corticosteroids   | 1,000-10,000       |
| Montelukast                                     | Asthma - preschool wheeze   | 50,000+            |
| Multiple Sclerosis (MS) Treatments              | Multiple Sclerosis (MS) - Amending entry criteria   | 100-1000           |
| Multiple Sclerosis (MS) Treatments              | Multiple Sclerosis (MS) - Removal of exit criteria  | 100-1000           |
| Multiple sclerosis (MS) treatments              | Multiple Sclerosis (MS) - Amending exit criteria  | 100-1000           |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical   | Funding Requested For  | Patient Population |
|--|--|--------------------|
| Multiple Sclerosis (MS) treatments   | Multiple Sclerosis (MS) - Amending treatment switching criteria                              | 100-1000           |
| Mycophenolate  | Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants | <100               |
| Naglazyme  | Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI, MPS VI), Enzyme replacement therapy (ERT) | <100               |
| Naltrexone   | Amending access criteria for alcohol dependence  | 1,000-10,000       |
| Naltrexone   | Henoch-Schonlein purpura (low dose)  | <100               |
| Naratriptan  | Acute migraine   | 10,000-50,000      |
| Nebulised hypertonic saline  | Cystic fibrosis  | 100-1000           |
| Niacin + Iaropirant (extended release)   | Hypercholesterolaemia and mixed dyslipidaemia  | <100               |
| Nilotinib  | Chronic Myeloid Leukaemia - after failure of imatinib  | <100               |
| Non-latex condoms  | Contraception  | 50,000+            |
| Octreotide   | Acromegaly - where surgery is contraindicated or awaiting effects of radiotherapy            | <100               |
| Octreotide   | Acromegaly - presurgery  | <100               |
| Octreotide   | TSH-producing pituitary adenomas   | <100               |
| Octreotide   | Nausea and vomiting from malignant bowel obstruction   | <100               |
| Olanzapine depot   | Schizophrenia- second line for patients who have failed on risperidone depot                 | 100-1000           |
| Olanzapine depot injection   | Schizophrenia  | 1,000-10,000       |
| Omalizumab   | Severe allergic asthma   | 100-1000           |
| Orablend   | Paediatric patients who cannot take oral tablet formulations                                 | 50,000+            |
| Oral feed (Fortijuce)  | Malnutrition   | 1,000-10,000       |
| Oral nutrient feed (fortisip compact)  | Malnutrition   | 1,000-10,000       |
| Oral supplement 1 Kcal/ml  | Oral supplement  | 1,000-10,000       |
| Oral supplement powder (Enprocal)  | Malnutrition and physical frailty  | 1,000-10,000       |
| Oxcarbazepine  | Epilepsy - second line after carbamazepine   | 1,000-10,000       |
| Oxybutynin patches (transdermal)   | Urinary incontinence   | 1,000-10,000       |
| Paediatric enteral feed - 0.75 kcal/ml with fibre RTH (Nutrini Low Energy Multi Fibre) | Low energy feed required   | 1,000-10,000       |
| Paediatric enteral feed 1.5 kcal with fibre RTH (Nutrini Energy Multi Fibre)           | Disease related malnutrition   | 1,000-10,000       |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical   | Funding Requested For  | Patient Population |
|--|--|--------------------|
| Paliperidone palmitate depot injection                                   | Schizophrenia  | 1,000-10,000       |
| Paliperidone tablets   | Schizophrenia second-line to risperidone or quetiapine   | 1,000-10,000       |
| Palivizumab  | Prevention of respiratory syncytial virus (RSV) infection in high risk infants                       | 10,000-50,000      |
| Paracetamol 500mg with codeine 30mg                                      | Pain   | 50,000+            |
| Paediatric oral feed 1 kcal/ml in 100ml Ready to Feed bottle (Infatrini) | Infants with increased nutritional requirements  | 1,000-10,000       |
| Pegylated liposomal doxorubicin  | Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy | 100-1000           |
| Pemetrexed disodium  | Non Small Cell Lung Cancer (NSCLC)   | <100               |
| Pipobroman   | Polycythaemia and essential thrombocythaemia   | <100               |
| PKU Gel  | Phenylketonuria (PKU)  | <100               |
| Potassium citrate  | Recurrent calcium oxalate urolithiasis   | 100-1000           |
| Pramipexole  | Parkinson's disease  | 1,000-10,000       |
| Prasugrel  | Acute Coronary Syndrome (ACS) with Percutaneous Coronary Intervention (PCI)                          | 1,000-10,000       |
| Protein drink - PKU cooler 10mg, 15mg, 20mg                              | Phenylketonuria (PKU)  | <100               |
| Protein drink MSUD   | Maple Syrup Urine Disease  | <100               |
| Quetiapine extended-release tablets                                      | Schizophrenia and bipolar disorder   | 1,000-10,000       |
| Raloxifene   | Osteoporosis - first line  | 10,000-50,000      |
| Raloxifene   | Osteoporosis in patients intolerant to bisphosphonates   | 1,000-10,000       |
| Ranibizumab  | Wet age-related macular degeneration   | 1,000-10,000       |
| Riluzole   | Amyotrophic lateral sclerosis  | 100-1000           |
| Risedronate  | Osteoporosis - first line  | 10,000-50,000      |
| Risedronate  | Paget's disease  | 1,000-10,000       |
| Rituximab  | Chronic Lymphocytic Leukaemia (CLL) - first line   | <100               |
| Rituximab  | Large cell lymphoma pts who have relapsed following prior non rituximab therapy                      | <100               |
| Rituximab  | Relapsed Chronic Lymphocytic Leukaemia - previously treated with rituximab                           | <100               |
| Rituximab  | Relapsed Chronic Lymphocytic Leukaemia - rituximab naïve   | <100               |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical                      | Funding Requested For  | Patient Population |
|-------------------------------------|--|--------------------|
| Rituximab                           | Indolent Non-Hodgkins Lymphoma (NHL) - retreatment                                       | 100-1000           |
| Rituximab                           | Large cell lymphoma - patients who have relapsed following prior rituximab therapy       | <100               |
| Rivaroxaban                         | Prevention of venous thrombosis following orthopaedic surgery                            | 1,000-10,000       |
| Rivastigmine capsules               | Alzheimer's disease (Dementia)   | 10,000-50,000      |
| Rivastigmine patches                | Alzheimer's disease (Dementia)   | 1,000-10,000       |
| Rosuvastatin                        | Hypercholesterolemia - third-line statin therapy   | 1,000-10,000       |
| Sertraline                          | Depression   | 10,000-50,000      |
| Sibutramine                         | Obesity  | 50,000+            |
| Sildenafil                          | Pulmonary arterial hypertension (PAH) secondary to other lung disease                    | 100-1000           |
| Sildenafil                          | Post-Fontan Repair   | <100               |
| Sildenafil                          | Pulmonary arterial hypertension (PAH) secondary to congenital diaphragmatic hernia (CDH) | <100               |
| Sildenafil                          | Pulmonary Arterial Hypertension (PAH) secondary to chronic lung disease (CLD)            | <100               |
| Sitagliptin                         | Type 2 diabetes  | 10,000-50,000      |
| Sitagliptin and Metformin           | Type 2 diabetes  | 10,000-50,000      |
| Sorafenib                           | Hepatocellular carcinoma   | 100-1000           |
| Sorafenib                           | Renal Cell Carcinoma   | <100               |
| Strontium ranelate                  | Osteoporosis - second line following bisphosphonates                                     | 1,000-10,000       |
| Sunitinib                           | Renal cell carcinoma   | <100               |
| Sunitinib                           | Gastrointestinal Stromal Tumour (GIST)   | <100               |
| Tamsulosin                          | Benign prostatic hyperplasia (BPH) in patients intolerant to alpha-blockers              | 1,000-10,000       |
| Telmisartan                         | Hypertension   | 50,000+            |
| Temozolomide                        | Anaplastic astrocytoma   | <100               |
| Temozolomide                        | Glioblastoma multiforme  | <100               |
| Tenofovir                           | Hepatitis B - Post liver transplant  | <100               |
| Tenofovir, emtricitabine            | HIV infection  | 1,000-10,000       |
| Tenofovir, emtricitabine, efavirenz | HIV infection  | 1,000-10,000       |
| Teriparatide                        | Osteoporosis - second-line following bisphosphonates                                     | 1,000-10,000       |
| Testosterone undecanoate injection  | Testosterone deficiency  | 100-1000           |
| Thalidomide                         | Multiple myeloma, first line for stem cell transplant ineligible                         | 100-1000           |

# PHARMAC

Pharmaceutical Management Agency

| Pharmaceutical   | Funding Requested For                                | Patient Population |
|--|--|--------------------|
| Thalidomide  | Multiple myeloma, Stem cell transplant eligible      | 100-1000           |
| Tolterodine and other formulations of oxybutynin (long acting and transdermal) | Overactive bladder                                   | 50,000+            |
| Trastuzumab  | Breast cancer - metastatic retreatment               | <100               |
| Travaprost and timolol   | Glaucoma   | 1,000-10,000       |
| Triamcinolone hexacetonide   | Intra-articular injection                            | 10,000-50,000      |
| TYR Cooler, tyrosine and phenylalanine free protein substitute                 | Tyrosinaemia   | <100               |
| Varenicline  | Nicotine addiction                                   | 1,000-10,000       |
| Vildagliptin   | Type 2 diabetes                                      | 10,000-50,000      |
| Vinorelbine (oral)   | Non-Small Cell Lung Cancer (NSCLC)                   | <100               |
| Vitamin D  | Vitamin D deficiency                                 | 10,000-50,000      |
| Vitamin D and Calcium  | Vitamin D deficiency and osteoporosis                | 10,000-50,000      |
| Zoledronic acid  | Osteoporosis - first line                            | 10,000-50,000      |
| Zoledronic acid  | Paget's disease                                      | 1,000-10,000       |
| Zoledronic acid  | Osteoporosis - second line following bisphosphonates | 1,000-10,000       |
| Zolmitriptan   | Acute migraine                                       | 10,000-50,000      |